Acquisition2025-05-16reported

Datavant × Aetion

Health data company Datavant acquired Aetion, a specialist in real-world evidence (RWE), to create an end-to-end platform for analyzing disparate health data sources. [35] The deal combines Datavant's data connectivity platform with Aetion's analytics software, which is used to answer research questions about the clinical impact of therapies. [35] One source reported the transaction as a leveraged buyout with an estimated value of $400 million, announced on July 11, 2025, while another reported the deal announcement on May 16, 2025. [35, 41]

Price paid
Not disclosed
Losing bid
Per unit
no meaningful ratio

The asset

Acquisition of Aetion, a healthcare analytics company with a platform for generating real-world evidence (RWE) from clinical and claims data to assess the safety, effectiveness, and value of medical treatments. [35, 41]

  • 300 data partners in combined ecosystem

The record

Seller status
Going concern
Sector
Real-world evidence and healthcare analytics
Modalities
real-world_data, clinical_data, claims_data
Jurisdiction
US
Personal data
Datavant's core business involves managing and sharing anonymised or de-identified patient data for life sciences and healthcare partners. [35]

What it means if you hold data

This acquisition represents a significant consolidation in the real-world evidence market, creating a powerful, integrated platform for life sciences companies. The deal highlights the increasing importance of combining data connectivity (accessing siloed datasets) with sophisticated analytics to generate regulatory-grade evidence for therapies. [35]

Sources